Results 211 to 220 of about 5,166,504 (245)

Early Postoperative Adverse Events (≤ 30 Days) in Spinal Oncology: Defining the Incidence, Severity, and Predictors in a Mixed Prospective Cohort Including Intradural and Metastatic Spinal Tumors

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Complication reporting in spinal tumor surgery remains inconsistently defined. We aimed to quantify the incidence, severity, and spectrum of early (≤ 30 days) postoperative adverse events (AEs) in spinal tumor surgery and to identify predictors of overall and serious complications using standardized severity grading.
Meltem Ivren   +6 more
wiley   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non‐Small Cell Lung Cancer

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administration of postoperative ...
Shinkichi Takamori   +12 more
wiley   +1 more source

Second Breast‐Conserving Treatment for Ipsilateral Breast Tumor Recurrence: A Review of Patient Selection, Reirradiation Techniques, and Clinical Outcomes

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Local recurrence after primary breast cancer treatment remains a complex clinical scenario in patients previously treated with breast‐conserving therapy and radiotherapy. For decades, salvage mastectomy was considered the standard treatment for ipsilateral breast tumor recurrence, largely because of concerns about local control after repeat ...
Cezara Cheptea   +4 more
wiley   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy